Phase 3 study for people with Endometrial Cancer

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor AstraZeneca
Registry number NCT07044336
Started 1 August 2025 Today 16 October 2026 Estimated completion 15 October 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Research Site Malvern VIC Recruiting
Research Site Melbourne VIC Recruiting
Research Site Randwick NSW Recruiting
Research Site St Leonards NSW Recruiting
Research Site Subiaco WA Recruiting
Research Site Westmead NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Female participants only
Healthy volunteers Not accepted
Enrolment target 800

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

The main inclusion criteria include but are not limited to the following:

* Histologically confirmed diagnosis of endometrial carcinoma or carcinosarcoma.

* Recurrent/metastatic EC ie, with radiological or objective evidence of recurrence or progression.

* Has received prior platinum-based chemotherapy and anti-programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination.

* A WHO/ECOG performance status of 0 or 1 at Screening.

* Has radiographically measurable disease by RECIST 1.1

The main exclusion criteria include but are not limited to the following:

* Had uterine sarcomas or uterine neuroendocrine carcinoma.

* Has had a recurrence of endometrial carcinoma or carcinosarcoma more than \> 12 months after completing platinum-based therapy administered in the curative-intent setting without any additional platinum-based therapy received in the recurrent setting.

* Had previously received treatment with any therapy (approved or investigational) that contained a TOP1i including ADCs .

* Had previously received treatment with Puxi-Sam or another B7-H4 targeting agent.

* History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.

* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.

* Active or previously documented autoimmune or inflammatory disorders

Dates on the record

Started 1 August 2025
Estimated completion 15 October 2027
Registry last updated 29 July 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 29 July 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.